MolecuLight Announces Presentation of its Clinical and Surgical Benefits in Reconstructive Plastic Surgery by Dr. Michael Desvigne at the 47th Annual JAB Maui Burn & Wound Symposium

MolecuLight Inc. Ontario

is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.

For sales, media or other inquiries or further information, please contact: Hunter Zudans, Director of Marketing, MolecuLight Inc., T. +1.484.682.7580, [e-mail], www.moleculight.com

Photo - https://mma.prnewswire.com/media/2607922/MolecuLight_MolecuLight_Announces_Presentation_of_its_Clinical_a.jpg

View original content:https://www.prnewswire.co.uk/news-releases/moleculight-announces-presentation-of-its-clinical-and-surgical-benefits-in-reconstructive-plastic-surgery-by-dr-michael-desvigne-at-the-47th-annual-jab-maui-burn--wound-symposium-302362331.html